Chemicals

Amyris to acquire Oobli, adding fermentation-derived sweet proteins to its platform

The planned deal combines Amyris’s strain engineering and manufacturing scale with Oobli’s sweet protein fermentation platform.

Miriam AchterbergNovember 16, 20265 min read7 views
Stainless-steel fermentation tanks and a stylized protein-and-fruit motif in a clean industrial setting.

Amyris, Inc. plans to acquire Oobli Inc., the Emeryville, Calif.-based biomanufacturing company announced, adding a fermentation-derived sweet protein platform to its portfolio. Oobli, based in Davis, Calif., develops sweet protein ingredients intended to help food and beverage brands reduce sugar without sacrificing taste. The acquisition is expected to close in the coming weeks.

Amyris described the transaction as a strategic commercial and technology expansion. The company said the deal brings together its scientific capabilities and manufacturing depth with Oobli’s protein fermentation expertise. It follows Amyris’s expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. Amyris said the acquisition would accelerate its footprint in protein- and peptide-based solutions across end markets.

Amyris CEO Kathy Fortmann said Oobli offers a commercial and technology platform that complements Amyris’s own. She said Oobli is positioned to change how sweetness reaches the market and that Amyris aims to bring commercial scale and resources to accelerate what the company calls the sweet revolution. Fortmann also said combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden capabilities in food and beverage, personal care, flavor and fragrances, agriculture and beyond.

Oobli’s commercial portfolio of sweet proteins is expected to be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process to produce sweet proteins naturally found in rare fruits and berries near the equator, according to the announcement. Oobli describes its sweet proteins as the first of their kind in the sugar-reduction category.

According to the announcement, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein. Oobli says they deliver sweetness without gut disruption or blood sugar spikes. The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, scientifically known as brazzein, monellin and thaumatin, respectively. The ingredients have FDA GRAS status and are FEMA GRAS-affirmed for use as a natural flavor, the announcement says.

The announcement points to food and beverage categories where brands are seeking sugar reduction, including sports and nutrition, dairy, beverages, chocolate, bakery and confectionery. It also cites growing consumer awareness of metabolic health. Oobli CEO Ali Wing said the company has long believed there was a better way to deliver sweet taste without trade-offs to health and the environment. She said joining Amyris would provide the scale and resources to pursue the ambition of making sweet proteins a global standard in sweetness solutions.

Fortmann said Amyris has seen that biomanufactured solutions succeed when they align with consumer demand and market needs. She said Oobli’s platform gives brands a way to address sweet taste, sugar reduction and clean label at the same time. Amyris said it looked forward to welcoming the Oobli team and realizing synergies between the two platforms.

The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships would continue to be honored without interruption as Oobli’s sweet protein portfolio expands within the company.